Skip to main content

Advertisement

SpringerLink
Log in

Functional neuroimaging in Alzheimer's disease: how far should we go?

  • Editorial
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Claus JJ, van Harskamp F, Breteler MMB, Keenning EP, van der Cammen TJM, Hofman A, Hasan D. Assessment of cerebral perfusion with single-photon emission tomography in normal subjects and in patients with Alzheimer's disease: effects of region of interest selection. Eur J Nucl Med 1994; 21: 1044–1051.

    Google Scholar 

  2. Mielke R, Pietrzyk U, Jacobs A, Fink GR, Ichimiya A, Kessler J, Herholz K, Heiss WD. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: comparison of perfusion and pattern. Eur J Nucl Med 1994; 21: 1052–1060.

    CAS  PubMed  Google Scholar 

  3. Goedert M, Potier MC, Spillantim MG. Molecular neuropathology of Alzheimer's disease. In: Kerwin R, ed. Cambridge medical reviews: neurobiology and psychiatry, vol 1. Cambridge: Cambridge University Press; 1991: 95–115.

    Google Scholar 

  4. Burns A, Philpot MP, Costa DC, et al. The investigation of Alzheimer's disease with single photon emission tomography. J Neurol Neurosurg Psychiatry 1989; 52: 248–253.

    Google Scholar 

  5. Spampinato U, Habert MO, Mas JL, et al. 99mTc-HMPAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Altheimer type. J Neurol Neurosurg Psychiatry 1991; 54: 787–792.

    Google Scholar 

  6. Hunter R, McLuskie R, Wyper D, et al. The pattern of function related regional cerebral blood flow investigated by single photon emission tomography with 99mTc-HMPAO in patients with presenile Alzheimer's disease and Korsakoff's psychosis. Psychol Med 1989; 19: 847–855.

    Google Scholar 

  7. Geaney DP, Soper N, Shepstone BJ, Cowen PJ. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer's disease. Lancet 1990; 335: 1484–1487.

    Google Scholar 

  8. Hardy J. Alzheimer's disease and the β-amyloid precursor protein. In: Kerwin R, ed. Cambridge medical reviews: neurobiology and psychiatry, vol 11, Cambridge: Cambridge University Press; 1993: 19–25.

    Google Scholar 

  9. Gallo JM. The biochemistry of tau proteins in Alzheimer's disease. In: Kerwin R, ed. Cambridge medical reviews: neurobiology and psychiatry, vol 11. Cambridge: Cambridge University Press; 1993; 27–42.

    Google Scholar 

  10. Eagger S, Morant M, Levy R, Sahakian B. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects. Br J Psychiatry 1992; 160: 36–40.

    Google Scholar 

  11. Stern GM. New drug intervention in Alzheimer's disease. Curr Opin Neurol Neurosurg 1992; 5: 100–103.

    Google Scholar 

  12. Cohen MB et al. SPECT brain imaging in Alzheimer's disease with oral tetrahydroaminoacridine and lecithin. Clin Nucl Med 1992; 17: 312–315.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Reader in Clinical Neuropharmacology, Institute of Psychiatry, De Crespigny Park, SE5 8AF, London, UK

    Robert Kerwin

Authors
  1. Robert Kerwin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kerwin, R. Functional neuroimaging in Alzheimer's disease: how far should we go?. Eur J Nucl Med 21, 1041–1043 (1994). https://doi.org/10.1007/BF00181057

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00181057

Search

Navigation